非小细胞肺癌早期诊断生物标志物的研究

Research on Biomarkers for Early Diagnosis of Non-Small Cell Lung Cancer

非小细胞肺癌（ non-small-cell-lung-cancer， NSCLC）的早期诊断是降低疾病高死亡率的一个关键因素。蛋白质、核酸、代谢物和肿瘤细胞的定量分析等技术的进步，使得研究人员能够发现新的高效的生物标志物以应用于NSCLC早期诊断，有益于临床治疗。文章分别介绍了近年来一些潜在的与NSCLC早期诊断相关的生物标志物：蛋白标志物（传统血清标志物、新兴循环自身抗体）， DNA生物标志物（癌基因抑癌基因突变、 DNA甲基化），小RNA作为标志物，这些标志物临床上联合检测及其一些常规的检测方法，有望为尽早确诊和治疗肺癌，开发新型基因治疗药物提供思路。

Early diagnosis of non-small-cell-lung-cancer （ NSCLC ） is the key to decreasing the NSCLC-related mortality.With the advances of the quantitative analysis of circulating proteins , nucleic acids , metabolites and tumor cells , novel biomarkers with high efficacy have been identified for use in the early diagnosis of NSCLC , which contributes to the clinical therapy.This study reviewed some potential biomarkers related to the early diagnosis of NSCLC： protein markers （ conventional serum markers and circulating autoantibodies ） , DNA biomarkers （ mutations of oncogenes or anti-oncogenes and methylation of DNA ） , and circulating microRNAs.Combined detection of these biomarkers and other conventional detection methods may help diagnose and treat lung cancer in early time, and provide clues for the development of new gene therapy drugs.